

28

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

LI *et al.*

Appl. No. 09/266,935

Filed: March 12, 1999

For: **Compositions and Methods for  
Enhanced Synthesis of Nucleic  
Acid Molecules**



Art Unit: 1655

Examiner: Riley, J.

Atty. Docket: 0942.4560001/RWE/BJD

**First Supplemental Information Disclosure Statement  
and Fee Under 37 C.F.R. § 1.97(c)**

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

Listed on accompanying Form PTO-1449 is a document that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98. A copy of the document is provided.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached PTO-1449 based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

04/10/2000 HLE111 00000008 09266935

02 FC:126

240.00 DP

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith. It is further understood that the Examiner will consider information that had been cited or submitted to the U.S. Patent and Trademark Office in a prior application relied on under 35 U.S.C. § 120. 1138 OG 37, 38 (May 19, 1992).

This Information Disclosure Statement is being filed after the mailing date of a first Office Action on the merits, but before the mailing of a final Office Action or Notice of Allowance. In accordance with 37 C.F.R. § 1.97(c), fee payment of \$240.00 is included in our check included herewith.

It is respectfully requested that the Examiner initial and return a copy of the enclosed PTO-1449, and to indicate in the official file wrapper of this patent application that the documents have been considered.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036. A duplicate copy of this pleading is enclosed.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

  
Brian J. Del Buono  
Agent for Applicants  
Registration No. 42,473

Date: April 6, 2000  
1100 New York Avenue, N.W.  
Suite 600

Washington, D.C. 20005-3934  
(202) 371-2600

P:\USERS\BRIAND\0942\4560001\040600.suppl.ids.wpd  
SKGF Rev. 1/26/98 clp

FORM PTO-1449 FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT		ATTY. DOCKET NO. 0942.4560001	APPLICATION NO. 09/266,935	
		APPLICANT Li et al.	O P E APR 06 2000 JC56	
		FILING DATE March 12, 1999	GROUP 1655	

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
AA							
AB							
AC							
AD							
AE							
AF							
AG							
AH							
AI							
AJ							
AK							

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
AL							Yes No
AM							Yes
AN							Yes
AO							Yes No
AP							Yes No

## OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

AR	13	Iakobashvili, R., and Lapidot, A., "Low temperature cycled PCR protocol for Klenow fragment of DNA polymerase I in the presence of proline," <i>Nucl. Acids Res.</i> 27:1566-1568 (March 1999).			
AS					
AT					

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.